stocks logo

RXRX

Recursion Pharmaceuticals Inc
$
6.490
+0.23(3.674%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
6.500
Open
6.200
VWAP
6.19
Vol
23.78M
Mkt Cap
2.81B
Low
5.930
Amount
147.27M
EV/EBITDA(TTM)
--
Total Shares
237.66M
EV
2.34B
EV/OCF(TTM)
--
P/S(TTM)
34.30
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
21.47M
+372.21%
-0.292
-44.97%
19.20M
-26.39%
-0.315
-7.35%
15.38M
+6.7%
-0.353
-11.67%
Estimates Revision
The market is revising Downward the revenue expectations for Recursion Pharmaceuticals, Inc. (RXRX) for FY2025, with the revenue forecasts being adjusted by -17.28% over the past three months. During the same period, the stock price has changed by 11.13%.
Revenue Estimates for FY2025
Revise Downward
down Image
-17.28%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-8.04%
In Past 3 Month
Stock Price
Go Up
up Image
+11.13%
In Past 3 Month
5 Analyst Rating
down Image
-3.70% Downside
Wall Street analysts forecast RXRX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for RXRX is 6.25 USD with a low forecast of 4.00 USD and a high forecast of 8.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
4 Hold
0 Sell
Hold
down Image
-3.70% Downside
Current: 6.490
sliders
Low
4.00
Averages
6.25
High
8.00
Morgan Stanley
Equal Weight
initiated
$5
2025-07-03
Reason
Morgan Stanley assumed coverage of Recursion Pharmaceuticals with an Equal Weight rating and $5 price target. Recursion has faced volatility due to a combination of macroeconomic factors, underperformance on initial clinical results and uncertainty on valuation and revenue drivers, the analyst tells investors in a research note. The recent pipeline prioritization and stage of clinical development for the proprietary pipeline leaves several open questions on valuation, the analyst tells investors in a research note.
Morgan Stanley
Equal Weight
downgrade
$8 -> $5
2025-06-17
Reason
Morgan Stanley lowered the firm's price target on Recursion Pharmaceuticals to $5 from $8 and keeps an Equal Weight rating on the shares. The firm revised its model following the company's recent pipeline prioritizations, cost reductions, 20% workforce reduction and updated cash burn guidance.
Morgan Stanley
Vikram Purohit
Hold
Maintains
$10 → $8
2025-04-10
Reason
Morgan Stanley lowered the firm's price target on Recursion Pharmaceuticals to $8 from $10 and keeps an Equal Weight rating on the shares. The firm updated its model based on commentary through Q4 earnings and following the recent opportunity it had to catch-up with management on the current status of the pipeline, the analyst tells investors.
Needham
Gil Blum
Strong Buy
Reiterates
$11
2025-04-08
Reason
Leerink Partners
Mani Foroohar
Hold
Maintains
$7 → $6
2025-02-28
Reason
Needham
Gil Blum
Strong Buy
Reiterates
$11
2025-02-06
Reason

Valuation Metrics

The current forward P/E ratio for Recursion Pharmaceuticals Inc (RXRX.O) is -5.12, compared to its 5-year average forward P/E of -7.78. For a more detailed relative valuation and DCF analysis to assess Recursion Pharmaceuticals Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-7.78
Current PE
-5.12
Overvalued PE
-1.43
Undervalued PE
-14.13

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-6.73
Current EV/EBITDA
-5.17
Overvalued EV/EBITDA
0.79
Undervalued EV/EBITDA
-14.25

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
89.59
Current PS
38.90
Overvalued PS
231.93
Undervalued PS
-52.75

Financials

Annual
Quarterly
FY2025Q1
YoY :
+6.89%
14.75M
Total Revenue
FY2025Q1
YoY :
+98.64%
-191.37M
Operating Profit
FY2025Q1
YoY :
+121.60%
-202.49M
Net Income after Tax
FY2025Q1
YoY :
+28.21%
-0.50
EPS - Diluted
FY2025Q1
YoY :
+22.80%
-133.79M
Free Cash Flow
FY2025Q1
YoY :
-352.18%
-48.04
Gross Profit Margin - %
FY2025Q1
-670.77
FCF Margin - %
FY2025Q1
YoY :
+107.31%
-1.37K
Net Margin - %

Trading Trends

Insider
Insiders areSelling! The selling amount has increased 246.83% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
1.4M
USD
5
6-9
Months
1.2M
USD
9
0-12
Months
1.6M
USD
19
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
449.5K
Volume
1
6-9
Months
7.7M
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
3
24.9M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

RXRX News & Events

Events Timeline

2025-07-21 (ET)
2025-07-21
12:00:26
Recursion Pharmaceuticals rises 10.7%
select
2025-07-21
10:00:03
Recursion Pharmaceuticals rises 16.8%
select
2025-07-08 (ET)
2025-07-08
08:13:26
Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M
select
Sign Up For More Events

News

3.5
07-26NASDAQ.COM
The Median Retirement Savings for American Households Is $87,000. Here Are 3 Incredible Stocks to Buy Now and Hold for Decades.
3.5
07-26Benzinga
Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills
3.5
07-25Benzinga
How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma
Sign Up For More News

FAQ

arrow icon

What is Recursion Pharmaceuticals Inc (RXRX) stock price today?

The current price of RXRX is 6.49 USD — it has increased 3.67 % in the last trading day.

arrow icon

What is Recursion Pharmaceuticals Inc (RXRX)'s business?

arrow icon

What is the price predicton of RXRX Stock?

arrow icon

What is Recursion Pharmaceuticals Inc (RXRX)'s revenue for the last quarter?

arrow icon

What is Recursion Pharmaceuticals Inc (RXRX)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Recursion Pharmaceuticals Inc (RXRX)'s fundamentals?

arrow icon

How many employees does Recursion Pharmaceuticals Inc (RXRX). have?

arrow icon

What is Recursion Pharmaceuticals Inc (RXRX) market cap?